1. Academic Validation
  2. Optimization of Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for Duration of Action, as an Inhaled Therapy for Lung Remodeling in Pulmonary Arterial Hypertension

Optimization of Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for Duration of Action, as an Inhaled Therapy for Lung Remodeling in Pulmonary Arterial Hypertension

  • J Med Chem. 2016 Sep 8;59(17):7901-14. doi: 10.1021/acs.jmedchem.6b00703.
Duncan E Shaw 1 Ferheen Baig Ian Bruce Sylvie Chamoin 2 Stephen P Collingwood Sarah Cross 1 Satish Dayal Peter Drückes 2 Pascal Furet 2 Vikki Furminger Deborah Haggart 3 Martin Hussey Irena Konstantinova Jon C Loren 3 Valentina Molteni 3 Sonia Roberts John Reilly Alex M Saunders Rowan Stringer Lilya Sviridenko Matthew Thomas Christopher G Thomson 1 Christine Tomlins Ben Wen 3 Vince Yeh 3 Andrew C Pearce
Affiliations

Affiliations

  • 1 Novartis Institutes of Biomedical Research (NIBR) , 100 Technology Square, Cambridge, Massachusetts 02139, United States.
  • 2 NIBR , Basel Fabrikstrasse 2, 4056 Basel, Switzerland.
  • 3 Genomics Institute of the Novartis Research Foundation , 10675 John Jay Hopkins Drive, San Diego, California 92121, United States.
Abstract

A series of potent PDGFR inhibitors has been identified. The series was optimized for duration of action in the lung. A novel kinase occupancy assay was used to directly measure target occupancy after i.t. dosing. Compound 25 shows 24 h occupancy of the PDGFR kinase domain, after a single i.t. dose and has efficacy at 0.03 mg/kg, in the rat moncrotaline model of pulmonary arterial hypertension. Examination of PK/PD data from the optimization effort has revealed in vitro:in vivo correlations which link duration of action in vivo with low permeability and high basicity and demonstrate that nonspecific binding to lung tissue increases with lipophilicity.

Figures
我们的 Cookie 政策

我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验,部分功能也使用 Cookies 帮助我们更好地理解您的需求,为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问,请阅读我们的《隐私声明》